Abstract
There is an enormous drive to refine therapeutic designs and delivery systems, but in this review we ask if this is always the right direction? We choose to play devil's advocate, and argue that refining drug design is not always needed, and what is actually needed is a greater understanding of the biology of the disease. Here we focus on asthma and the β2-agonist group of bronchodilators as an example of how a class of therapeutic has been developed and continues to be developmentally refined. In this review, we define viralinduced exacerbations as the greatest cause of lung attacks and the most crucial time β2-agonist therapy is needed. We explore the reasons why β2-agonist therapy fails in patients with rhinovirus-induced exacerbations, and explain why further “engineered” β2-agonist therapies are likely to continue to fail in this subset of asthmatic population. We justify our perspective by returning to the biology that underlies the cause of disease and highlight the need for “more research” into alternative therapies for this population of asthmatic patients.
Keywords: β2-agonists, desensitization, exacerbations, leukotrienes, prostaglandins, rhinovirus.
Current Drug Delivery
Title:Do We Really Need to Keep Redesigning β2-agonists for the Management of Asthma?
Volume: 12 Issue: 1
Author(s): David Van Ly and Brian G.G. Oliver
Affiliation:
Keywords: β2-agonists, desensitization, exacerbations, leukotrienes, prostaglandins, rhinovirus.
Abstract: There is an enormous drive to refine therapeutic designs and delivery systems, but in this review we ask if this is always the right direction? We choose to play devil's advocate, and argue that refining drug design is not always needed, and what is actually needed is a greater understanding of the biology of the disease. Here we focus on asthma and the β2-agonist group of bronchodilators as an example of how a class of therapeutic has been developed and continues to be developmentally refined. In this review, we define viralinduced exacerbations as the greatest cause of lung attacks and the most crucial time β2-agonist therapy is needed. We explore the reasons why β2-agonist therapy fails in patients with rhinovirus-induced exacerbations, and explain why further “engineered” β2-agonist therapies are likely to continue to fail in this subset of asthmatic population. We justify our perspective by returning to the biology that underlies the cause of disease and highlight the need for “more research” into alternative therapies for this population of asthmatic patients.
Export Options
About this article
Cite this article as:
Ly Van David and Oliver G.G. Brian, Do We Really Need to Keep Redesigning β2-agonists for the Management of Asthma?, Current Drug Delivery 2015; 12 (1) . https://dx.doi.org/10.2174/1567201811666140606112918
DOI https://dx.doi.org/10.2174/1567201811666140606112918 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER<sup>©</sup>) as Monotherapy for Chronic PTSD: A Pilot Study
Adolescent Psychiatry Advances in the Development of Bradykinin Receptor Ligands
Current Topics in Medicinal Chemistry An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Role of Toll-Like Receptors in Immune Responses to Chlamydial Infections
Current Pharmaceutical Design Potential Role of Antibiotics in the Treatment of Asthma
Current Drug Targets - Inflammation & Allergy Editorial: The Diagnosis and Management of Asthma: Are We Moving in the Right Direction?
Current Respiratory Medicine Reviews Editorial [ Hot Topic:Immunomodulation in Helminth Infections
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effect of Pharmacotherapy for Attention Deficit Hyperactivity Disorder on Risk of Seizures in Pediatric Patients as Assessed in an Insurance Claims Database
Current Drug Safety Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy
Current Drug Metabolism Monoclonal Antibody-based Genetic Immunotherapy
Current Gene Therapy 3D QSAR Pharmacophore, CoMFA and CoMSIA Based Design and Docking Studies on Phenyl Alkyl Ketones as Inhibitors of Phosphodiesterase 4
Medicinal Chemistry A Review of Recent Patents on the ASICs as a Key Drug Target
Recent Patents on Biotechnology Current Update on Eosinophilic Lung Diseases and Anti-IL-5 Treatment
Recent Patents on Anti-Infective Drug Discovery Modified Pulsincap of Ibuprofen - A Novel Approach for Chronotherapy
Current Drug Delivery Modulation of Mast Cell and Basophil Functions by Benzene Metabolites
Current Pharmaceutical Design Anti Citrullinated Protein Antibodies and Mechanism of Action of Common Disease Modifying Drugs - Insights in Pathomechanisms of Autoimmunity
Current Pharmaceutical Design Appreciating the Balance between Classical Interleukin (IL)-6 Receptor Signaling and IL-6 Trans-Signaling: Implications for Arthritis Progression
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Effect of Antenatal Steroids on Haemodynamics in the Normally Grown and Growth Restricted Fetus
Current Pediatric Reviews Safety of Inhaled Corticosteroids. Why the Variation in Systemic Adverse Effects?
Current Pediatric Reviews Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets